Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020

SAN DIEGO, June 16, 2020 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbody™, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was […]

PHANES THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO

Company will showcase its bispecific antibody platform PACbody™ and immuno-oncology pipeline ​San Diego, California/December 12, 2019 – Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery in immuno-oncology, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in […]

PHANES AND FOSUN KITE FORM STRATEGIC ALLIANCE FOR INNOVATIVE CAR-T PRODUCTS TO TREAT SOLID TUMORS

Phanes Therapeutics and Phanes Biopharmaceuticals (“Phanes”) recently formed an important strategic alliance with Fosun Kite Biotechnology (“Fosun Kite”). Under the alliance agreement, Phanes will exclusively provide Fosun Kite a collection of all high-affinity humanized antibodies targeting two novel cancer antigens for the development and commercialization of innovative CAR-T products for solid tumor treatments in China […]

PHANES AND HANMI ANNOUNCE LICENSING AGREEMENT TO DEVELOP BI- AND/OR MULTI-SPECIFIC ANTIBODIES

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has signed a licensing agreement with Hanmi Pharmaceutical Co., LTD (Hanmi), a well-known global player in the biopharmaceutical field, for the development of bi- and/or multi-specific antibodies for immuno-oncology applications. Under the terms of the agreement, Hanmi will […]

MERCK TO PROVIDE BIORELIANCE® END-TO-END SOLUTIONS TO PHANES THERAPEUTICS

Collaboration to accelerate development and manufacturing of Bispecific Antibody Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering Shanghai, China, July 24, 2019 – Merck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding (MoU) with Phanes Therapeutics, Inc. (Phanes) for […]

CROWNBIO ENTERS STRATEGIC PARTNERSHIP WITH PHANES THERAPEUTICS TO ACCELERATE DISCOVERY AND DEVELOPMENT OF PHANES’ NOVEL ONCOLOGY AGENTS

Original link: https://blog.crownbio.com/press/partnership-with-phanes (San Diego, Calif., March 13, 2018) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic […]

WUXI BIOLOGICS AND PHANES ANNOUNCE STRATEGIC PARTNERSHIP

Shanghai and San Diego, Dec. 14, 2017 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Phanes Therapeutics, Inc. (Phanes), an innovative drug discovery company based in San Diego, announced today that an MOU was signed to form a strategic biologics development […]